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Abstract Urea cycle disorders (UCDs) result from
inherited defects in the ammonia detoxification pathway,
leading to episodes of hyperammonaemia and encephalop-
athy. The purpose of this study was to answer the question,
“what is the likely plasma amino acid profile of a patient
known to have a UCD presenting with hyperammonaemia
during acute metabolic decompensation”, in order to support
informed decisions regarding management.
We analysed the results of plasma ammonia levels and
amino acid profiles taken simultaneously or within 30 min
of each other during acute admissions of all patients
with a UCD at the Royal Children’s Hospital, Melbourne,
over 28 years. Samples from 96 admissions (79, 9 and
8 admissions for OTC, CPS and ASS deficiencies,
respectively) from 14 patients fulfilled these criteria. Amino
acid levels were measured by ion exchange chromato-
graphy with post-column ninhydrin derivatisation and
interpreted in relation to age-related reference ranges.
Plasma concentrations of all measured essential amino
acids were low or low-normal in almost all samples. There
was a strong positive correlation between low plasma
branched-chain amino acids and other essential amino
acids, and a negative correlation between ammonia and
phenylalanine to tyrosine (Phe:Tyr) ratio in patients with
OTC deficiency, and between glutamine and Phe:Tyr ratio
in all patients, indicating protein deficiency.
Conclusion: At admission, protein deficiency is common
in patients with a UCD with hyperammonaemia. These
results challenge the current guideline of stopping protein
intake during acute decompensation in UCDs. Supple-
mentation with essential amino acids (particularly
branched-chain amino acids) at these times should be
considered.
Introduction
Urea cycle disorders (UCDs) result from inherited defects in
the hepatic ammonia detoxification pathway. The six urea
cycle enzymes are carbamoyl phosphate synthetase I (CPS I)
and its allosteric activator N-acetylglutamate synthetase
(NAGS), ornithine transcarbamylase (OTC), argininosuc-
cinic acid synthetase (ASS), argininosuccinic acid lyase
(ASL), and arginase (ARG) (Leonard 2000). The clinical
manifestations of these disorders are variable and UCD
phenotypes range from neonates dying of the complications
of hyperammonaemia in the first week of life to apparently
asymptomatic adults. These disorders may lead to episodes
of hyperammonaemia and encephalopathy during metabolic
decompensation, which may occur at any age. Patients are
treated with a normal-high calorie, low-protein diet and
nitrogen-scavenging medications (sodium benzoate and/or
sodium phenylbutyrate). Arginine, which becomes an
essential amino acid in patients with a UCD (except for
argininaemia), is also provided in sufficient amounts to
overcome potential deficiency (Leonard and Morris 2002).
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Amino acid profiles are a powerful determinant in the
management of patients with a UCD and are considered a
requisite in the follow-up of these patients (Leonard 2001;
Summar 2001). However, there are very few published
reports in which sufficient attention has been given to the
timing of blood sampling (fasting hours), in order to obtain
meaningful blood concentrations that can serve for thera-
peutic decision making. This study aimed to examine the
relationships between plasma ammonia and amino acid
profiles of patients with a UCD admitted during acute
decompensation, in order to answer the question, “what is
the likely plasma amino acid profile of a patient known to
have a UCD presenting with hyperammonaemia during
acute metabolic decompensation”, and thus to facilitate a
preferred therapeutic decision. We also wanted to identify
possible correlations between ammonia and specific amino
acids at the time of decompensation.
Methods
We reviewed the results of plasma ammonia levels and
amino acid profiles of all patients with a known UCD
admitted to the Royal Children’s Hospital, Melbourne, due
to metabolic decompensation, from January 1982 to
December 2010. All patients have been treated in one
centre under the same therapeutic protocol: protein restric-
tion whilst providing sufficient energy intake, sodium
benzoate and arginine (some patients with OTC deficiency
were treated with citrulline for a short period). During acute
admissions due to hyperammonaemia, protein intake is
stopped for up to 24 h and is gradually re-introduced
thereafter. Energy (calorie) intake is increased to >100%
recommended daily intake. Sodium benzoate and arginine
are given at a loading dose, followed by maintenance daily
dose. The institutional ethics committee approved the study
(HREC 32082A).
Inclusion criteria in this study were all acute admissions
where plasma amino acid profiles and ammonia concen-
trations were undertaken simultaneously or within 30 min
of each other. Information regarding the patients and the
number of samples obtained from each is provided in
Table 1. Seven patients with OTC (one male) provided
1–37 samples each; four patients with CPS I deficiency
(one female) provided 1–6 samples each; three patients
with ASS deficiency (one female) provided 1–4 samples.
All samples for ammonia and amino acids were taken and
analysed at the same site. Ammonia levels and plasma
amino acid profiles were determined under the same
protocols during these years. Amino acid concentrations
were measured by ion exchange chromatography with post
column ninhydrin derivatisation. Sequential models of
Biochrom amino acid analysers have been used during the
period in review. Quality assurance and validation testing
were undertaken during transition between machines, using
Sigma Aldrich standards and complying with external
quality control programmes, as required for laboratory
accreditation. Due to the fact that normal values of each
Table 1 Clinical details and number of samples from patients with UCD (*Patient found to have mosaic c.533 C>T (p.T178M) mutation.
Mosaicism estimated at 50% based on hair root follicles and saliva specimen)







1 CPS I deficiency Female 4 years 2 months Mutation 1 0
2 CPS I deficiency Male 6 years 2 months Mutation 1 0
3 CPS I deficiency Male 7 years 9 months Mutation 1 0
4 CPS I deficiency Male 15 years 4 months Mutation 0 6
5 OTC deficiency Female 15 years Biochemical
(cascade screening)
0 7
6 OTC deficiency Female 12 years 4 months Mutation 2 16
7 OTC deficiency Female 7 years 10 months Biochemical
(cascade screening)
2 0
8 OTC deficiency Female 9 years 1 month Mutation 34 3
9 OTC deficiency Male 8 years 9 months Mutation* 11 1
10 OTC deficiency Female Deceased Biochemical
(cascade screening)
0 2
11 OTC deficiency Female 2 years 9 months Mutation 1 0
12 ASS deficiency Male Deceased Biochemical 1 0
13 ASS deficiency Male 30 years 2 months Biochemical
(cascade screening)
3 0
14 ASS deficiency Female Deceased Biochemical 4 0
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amino acid vary with age, correlations were performed in
two age groups of less than 6 and greater than 6 years, as
per the two age-related normal ranges of our laboratory,
which are based on Armstrong and Stave (1973) and
Applegarth et al. (1979). There were only four samples
from infants <3 months old (three neonates) and their
results were incorporated within the <6-year-old group of
patients. Each plasma amino acid concentration was first
compared to the relevant reference range and then corre-
lated to other amino acids and to ammonia. Ratios of
particular amino acids were then calculated to determine the
extent of any correlation with ammonia or glutamine.
Amino acids were also divided into groups: Branched-
Chain Amino Acids (BCAA), Large Neutral Amino Acids
(LNAA), Essential Amino Acids (EAA) and Non-Essential
Amino Acids (NEAA). Due to the absence of some amino
acids from the profiles provided by our laboratory, EAA
comprised valine, isoleucine, leucine, phenylalanine, threo-
nine, tyrosine, methionine, lysine and histidine, but not
tryptophan.
Data analysis and graphing was performed in Excel
2007® (Microsoft, Seattle, WA, USA) using native corre-
lation and regression analysis together with the Analyse-It®
add-on (www.analyse-it.com). Descriptive statistics includ-
ing medians and interquartile ranges were calculated.
Standard statistical tests used included Spearman’s rank,
together with two-tailed p-value calculation. We used the
Šida´k Correction to correct for the large number of
comparisons; thus a stringent p-value of 0.004 or less was
deemed significant.
Results
Samples from 96 admissions (79, 9 and 8 admissions for
OTC, CPS and ASS deficiencies, respectively; none from
ASL deficiency) from 14 patients fulfilled the inclusion
criteria.
Figure 1a and 1b depicts the concentrations of each
amino acid in the OTC-deficient group (the largest in our
cohort), compared with an age-specific reference range.
Plasma concentrations of ammonia, glutamine and citrulline
in patients with CPS I, OTC and ASS deficiencies are
presented in Table 2 (a small number of samples from
patients with OTC deficiency were taken at the period when
these patients were treated with citrulline, leading to a wide
range of plasma citrulline concentrations in this group but a
low median concentration, as would be expected).
Plasma concentration of most amino acids, particularly
the essential amino acids, was low-normal or low. All three
BCAAwere below the normal range in 35/96 (36.5%) of all
samples and in 30/79 (38.0%) of OTC-deficient patients. Of
the BCAA, valine concentration was most frequently low
(in 57/96 (59.4%) of all samples and 51/79 (64.9%) of
OTC-deficient patients), and by the greatest margin when
compared with its reference range.
Glutamate concentration was above the normal range in
38/96 (39.6%) of all patients and 31/79 (39.2%) of OTC-
deficient patients. Valine concentration was low in 27/38
(71%) and 24/31 (77.4%) of these samples, respectively.
Leucine concentration was low in 25/38 (65.8%) and 21/31
(67.7%) of these samples, respectively, and isoleucine was
low in 23/38 (60.5%) and 18/31 (58.1%), respectively.
Plasma alanine concentrations were above the normal
range in 23/96 (24.0%) of all samples and 20/79 (25.3%) of
OTC-deficient patients. The plasma concentration of other
amino acids varied. Arginine concentration varied, as
would be expected given that the patients may or may not
have had a dose of arginine just prior to coming to hospital.
Ammonia concentration correlated with glutamine con-
centration in samples from all patients and in those with
OTC deficiency, particularly those who were <6 years old
(r ¼ 0.5 p < 0.0001 and r ¼ 0.53 p < 0.0001,
respectively) (Table 3; Fig. 2), but not in samples from
children >6 years of age. There was only a trend towards a
correlation between glutamine and ammonia in the CPS
deficiency group (all patients: r ¼ 0.70 p ¼ 0.0347; there
were only three samples of patients <6 years, too few to
calculate a meaningful Spearman’s Rank; patients >6 years
of age: r ¼ 0.61 p ¼ 0.1997). There was no correlation
between glutamine and ammonia in the ASS deficiency
group (r ¼ 0.17 p ¼ 0.693). Glutamine concentration was
above the normal age-specific range in 87/96 (90.6%) of all
samples and in 76/79 (96.2%) of patients with OTC
deficiency. Given that there is a continuum of changes in
amino acid concentrations in blood (and that the cut-off
point between <6 and >6 is somewhat arbitrary), we
explored the relationship between glutamine and age. A
trend towards some correlation was found in OTC-deficient
patients (r ¼ 0.28; p ¼ 0.0122) but not in other groups.
There was a trend towards a negative correlation
between glutamine and glutamate in the >6 year old
patients in the whole cohort (r ¼ 0.4; p ¼ 0.0206) and
in the OTC-deficient patients (r ¼ 0.47; p ¼ 0.0117), but
not in the younger group.
The Phe:Tyr ratio has been used as a marker for protein
turnover and whole body protein balance (de Betue et al.
2011). There was a negative correlation between glutamine
and Phe:Tyr ratio (r ¼ 0.34; p ¼ 0.0008), particularly in
the <6 year old age group (r ¼ 0.45; p ¼ 0.0003), which
was very similar in the young OTC-deficient patients (r ¼
0.49; p ¼ 0.0003) (Fig. 3). There was a somewhat smaller
negative correlation between ammonia and Phe:Tyr ratio in
this age group (r ¼ 0.3; p ¼ 0.0205), which was stronger
in the OTC-deficient patients (r ¼ 0.48; p ¼ 0.0004)
(Fig. 4). These correlations were not noted in older children.
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There was a strong correlation between BCAA concen-
trations and those of other essential amino acids in the
whole cohort, regardless of age (Table 3). There were only
4 out of 35 samples where the concentrations of all BCAA
were low while those of the other essential amino acids
(phenylalanine, tyrosine and threonine) were normal.
There was a strong correlation between plasma alanine
and proline concentrations in all patients (r ¼ 0.6; p <
0.0001), which was more obvious in patients of >6 years of
age (r ¼ 0.74; p < 0.0001) (Table 3). Plasma alanine
concentrations did not correlate with ammonia concentra-
tions (Table 3).
Discussion
Amino acid profiles are a powerful determinant in the
management of patients with a UCD and are considered a
requisite in the follow-up of these patients (Leonard 2001;
Summar and Tuchman 2001). The rationale for this study
was to provide information about the most likely plasma
amino acid pattern in patients with a UCD at the time of
decompensation and presentation to hospital, in order to
guide appropriate treatment prescription. To this end, we
reviewed the results of plasma amino acid profiles
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Fig. 1 Plasma amino acids concentrations in patients with OTC deficiency < 6 years old (a) and > 6 years old (b). Boxes represent interquartile
ranges. Horizontal bars within boxes represent the median. Vertical bars represent the range of concentrations
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hyperammonaemia, as a common denominator. To the best
of our knowledge, this is the first study to document plasma
amino acid profiles at times of decompensation, as opposed
to chronic follow-up management. Statistical analysis of the
results indicates that the correlations found when considering
just OTC-deficient patients are stronger than when
Table 2 Ammonia, glutamine and citrulline concentrations (in mmol/L) in blood samples from patients with CPS I, OTC and ASS deficiencies
CPS I <6 years
n ¼ 3











Ammonia Median value ¼ 86;
range ¼ 37–231;
IQR ¼ 62–159
Median value ¼ 131;
range ¼ 17–171;
IQR ¼ 67–154
Median value ¼ 172;
range ¼ 23–479;
IQR ¼ 109–241
Median value ¼ 167;
range ¼ 38–389;
IQR ¼ 93–243





Glutamine Median value ¼ 780;
range ¼ 662–933;
IQR ¼ 721–857
Median value ¼ 846;
range¼ 607–920.9;
IQR ¼ 710–897
Median value ¼ 1061;
range ¼ 688–1658;
IQR ¼ 919–1,250








Citrulline Median value ¼ 7;
range¼ 4–9;
IQR ¼ 6–8
Median value ¼ 7;
range¼ 4–263;
IQR ¼ 5–167
Median value ¼ 26;
range¼7–497;
IQR ¼ 14–66
Median value ¼ 32;
range¼ 5–578;
IQR ¼ 13–69






Table 3 Spearman Rank correlations (r) between ammonia and amino acids and between amino acids themselves in all patients and in patients
with OTC deficiency, based on age groups (* ¼ p< 0.004)
All patients (CPS, OTC, ASS deficiency) OTC deficiency
All ages <6 years 6–18 years All ages <6 years 6–18 years
Ammonia GLN r 0.33 0.5 0.08 0.27 0.53 0.17
p * * 0.64 0.01 * 0.37
Ammonia PHE:TYR r 0.24 0.3 0.18 0.4 0.48 0.25
p 0.01 0.02 0.29 * * 0.19
GLN GLU r 0 0.26 0.4 0.08 0.19 0.47
p 0.97 0.04 0.02 0.46 0.17 0.01
GLN PHE:TYR r 0.34 0.45 0 0.43 0.49 0.1
p * * 0.98 * * 0.61
BCAA# PHE r 0.47 0.47 0.41 0.6 0.49 0.62
p * * 0.01 * * *
BCAA# TYR r 0.59 0.5 0.59 0.75 0.68 0.71
p * * * * * *
BCAA# THR r 0.53 0.44 0.57 0.7 0.57 0.77
p * * * * * *
BCAA# LYS r 0.52 0.49 0.40 0.57 0.54 0.41
p * * 0.01 * * 0.03
BCAA# HIS r 0.24 0.33 0.13 0.43 0.39 0.36
p 0.01 0.01 0.47 * 0.01 0.05
BCAA# MET r 0.32 0.48 0.03 0.47 0.49 0.23
p * * 0.86 * * 0.22
ALA GLN r 0.33 0.39 0.18 0.32 0.38 0.14
p * * 0.30 0.05 0.07 0.46
ALA PRO r 0.6 0.54 0.74 0.65 0.59 0.85
p * * * * * *
ALA Ammonia r 0.11 0.02 0.32 0.11 0.05 0.27
p 0.27 0.87 0.05 0.31 0.74 0.15
#BCAA ¼ Molar sum of LEU, ILE, VAL
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considering the whole cohort. This could be incidental, but it
raises the question as to whether there might be alternative
significant correlations within the other UCDs. Further
analysis of many more samples from more patients is
required in order to answer this question.
Previous studies have demonstrated that patients with a
UCD may have low plasma concentrations of BCAA. One
reason for this finding is transamination of BCAA to form
glutamate from alpha-ketoglutarate, as a pivotal step in the
formation of glutamine and ammonia detoxification. As a
result, there is enhanced oxidation of these amino acids in
muscle during hyperammonaemia (Holecek et al. 2011).
Treatment with sodium phenylacetate/phenylbutyrate has
been shown to further deplete BCAA availability (Scaglia
et al. 2004; Scaglia 2010). In our cohort, in which no
patient is or has been treated with sodium phenylbutyrate,
low concentrations of BCAA correlated with low concen-
trations of other essential amino acids, suggesting general
protein deficiency at the time of decompensation. Of
particular note is the strong correlation between the
concentrations of BCAA and the concentrations of phenyl-
alanine, tyrosine, threonine and other large neutral amino
acids, demonstrating that plasma levels of these amino
acids are proportionately low. Further support for the notion
of protein deficiency at presentation in the emergency
department is found in the disproportionately lower valine
levels, compared with leucine and Isoleucine (Adibi 1976).
These observations are not surprising, given that samples
were taken at admission for hyperammonaemia, possibly
following an intercurrent illness with low protein intake and
a drive towards glutamine production (calorie intake could
vary, depending on the patient’s ability to consume high
calorie formulae, as instructed when unwell). These results
suggest that, unless reduced in parallel with other essential
amino acids (suggesting a generalised protein deficiency),
BCAA deficiency is likely to be the result of their enhanced
disposal, such as with the use of sodium phenylbutyrate
(Scaglia 2010).
The negative correlation between ammonia concentra-
tion and Phe:Tyr ratio in our samples, particularly in the <6
year old age group, lends support for the notion of a
correlation between hyperammonaemia and protein defi-
ciency (de Betue et al. 2011). Although plasma amino acid
profiles measured at the time of decompensation may not
Fig. 2 Correlation between Ammonia and Glutamine in patients <6
years of age. Diamond ¼ OTC deficiency. Triangle ¼ ASS deficiency.
Cross ¼ CPS I deficiency
Fig. 3 Correlation between Glutamine and Phe:Tyr in patients <6
years of age. Diamond ¼ OTC deficiency. Triangle ¼ ASS deficiency.
Cross ¼ CPS I deficiency
Fig. 4 Correlation between Ammonia and Phe:Tyr in patients <6
years of age. Diamond ¼ OTC deficiency. Triangle ¼ ASS deficiency.
Cross ¼ CPS I deficiency
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be appropriate for determining chronic protein deficiency,
this finding can be extrapolated to highlight the risk of
hyperammonaemia in chronic protein malnutrition due to a
very restricted low-protein diet, as previously reported
(Bachmann 2005). This notion should lead to careful
individual monitoring of each patient, to avoid over-
treatment, particularly given the documented protein aver-
sion of patients with a UCD (Gardeitchik et al. 2012).
The observations of a correlation between age and
metabolite concentration, and in particular the correlations
between metabolites in one age group and not the other,
may shed light on some of the previous findings reported in
the literature. For example, Wilson et al. have shown that at
high plasma glutamine concentrations, ammonia concen-
trations vary. They suggested that a possible reason for this
was that glutamine synthetase, which converts glutamate
and ammonia to glutamine, has a high affinity but low
capacity for ammonia (H€aussinger et al. 1992), and when it
reaches its capacity for glutamine synthesis, ammonia
levels can fluctuate wildly, due to the diminished effect of
the glutamate/glutamine buffering system. Our results are in
agreement with those of Wilson et al. (2001), but we found
that the correlation between ammonia and glutamine is age
dependent and appears to be limited to the <6-year-old age
group (Table 1; Fig. 2). It should be noted that the number
of samples from ASS-deficient patients available to us was
too small to enable a comparison of the correlation between
ammonia and glutamine in these samples and those from
OTC-deficient patients (Wilson et al. 2001). Plasma
concentrations of glutamine and glutamate do not necessar-
ily reflect their concentrations in other compartments (such
as muscle, hepatic periportal and perivenous zones,
intestine and kidney), and therefore interpretation of these
findings is limited. Nevertheless, these results suggest that
pathophysiological mechanisms could be somewhat differ-
ent in the two age groups, and therapeutic considerations
may need to be age related.
We conclude that the majority of UCD patients are
protein deficient at admission with hyperammonaemia, as
shown by the low plasma levels of most amino acids, the
disproportionately low valine concentration and the nega-
tive correlation between ammonia and Phe:Tyr ratio (de
Betue et al. 2011). Current recommendations for the
management of patients with a UCD who present with
hyperammonaemia include cessation of protein intake for
up to 24 h (Leonard 2000) while providing sufficient
calories to prevent catabolism. The findings in this study
challenge the notion of stopping all protein intake.
Providing enteral BCAA, in particular leucine, has been
shown to increase protein synthesis in the liver (de Betue
et al. 2011) (reviewed in Bachmann (2008)). Thus, in order
to enhance anabolism, supplementation of essential amino
acids enriched with BCAA along with sufficient calories to
patients with a UCD during acute decompensation and
hyperammonaemia would seem prudent. Moreover, in view
of the contribution of the splanchnic system to protein
retention and metabolism (Newsholme et al. 2003), it
would be advantageous to treat patients who present with
metabolic decompensation through enteral supplementa-
tion, as previously suggested (Leonard 2001; Summar
2001), rather than intravenously.
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